Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report
Open Access
- 23 November 2001
- journal article
- case report
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 1 (1) , 22
- https://doi.org/10.1186/1471-2334-1-22
Abstract
Mucormycosis (or zygomycosis) is the term for infection caused by fungi of the order Mucorales. Mucoraceae may produce severe disease in susceptible individuals, notably patients with diabetes and leukemia. Rhinocerebral mucormycosis most commonly manifests itself in the setting of poorly controlled diabetes, especially with ketoacidosis. A 31-year-old diabetic man presented to the outpatient clinic with the following signs and symptoms: headache, periorbital pain, swelling and loss of vision in the right eye. On physical examination his right eye was red and swollen. There was periorbital cellulitis and the conjunctiva was edematous. KOH preparation of purulent discharge showed broad, ribbonlike, aseptate hyphae when examined under a fluorescence microscope. Cranial MRI showed involvement of the right orbit, thrombosis in cavernous sinus and infiltrates at ethmoid and maxillary sinuses. Mucormycosis was diagnosed based on these findings. Amphotericin B (AmBisome®; 2 mg/kg.d) was initiated after the test doses. Right orbitectomy and right partial maxillectomy were performed; the lesions in ethmoid and maxillary sinuses were removed. The duration of the liposomal amphotericin B therapy was approximately 6 months and the total dose of liposomal amphotericin B used was 32 grams. Liposomal amphotericin B therapy was stopped six months later and oral fluconazole was started. Although a total surgical debridement of the lesions could not be performed, it is remarkable that regression of the disease could be achieved with medical therapy alone.Keywords
This publication has 17 references indexed in Scilit:
- Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 CasesClinical Infectious Diseases, 1998
- Limited Toxicity of Prolonged Therapy with High Doses of Amphotericin B Lipid ComplexClinical Infectious Diseases, 1995
- Fluconazole in the treatment of three cases of mucormycosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Another Case Report of Rhinocerebral Mucormycosis Treated with Liposomal Amphotericin B and SurgeryClinical Infectious Diseases, 1994
- A Case of Chronic Progressive Rhinocerebral Mucormycosis Treated with Liposomal Amphotericin B and SurgeryClinical Infectious Diseases, 1993
- MucormycosisClinical Infectious Diseases, 1992
- Amphotericin B: delivery systemsAntimicrobial Agents and Chemotherapy, 1990
- Amphotericin B: 30 Years of Clinical ExperienceClinical Infectious Diseases, 1990
- Fluconazole therapy for pulmonary mucormycosis complicating.Japanese Journal of Medicine, 1989
- Improved Diagnosis and Prognosis of MucormyucosisMedicine, 1986